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Abstract 
 
BACKGROUND:  Disease-modifying therapies are urgently needed for the treatment of Alzheimer’s 
disease (AD).  The European Union/United States (EU/US) Task Force represents a broad range of 
stakeholders including biopharma industry personnel, academicians, and regulatory authorities.  
OBJECTIVES:  The EU/US Task Force represents a community of knowledgeable individuals who 
can inform views of evidence supporting disease modification and the development of disease-
modifying therapies (DMTs).  We queried their attitudes toward clinical trial design and 
biomarkers in support of DMTs. 
DESIGN/SETTING/PARTICIANTS:  A survey of members of the EU/US Alzheimer’s Disease Task 
Force was conducted.  Ninety-three members (87%) responded.  The details were analyzed to 
understand what clinical trial design and biomarker data support disease modification.   
MEASUREMENTS/RESULTS/CONCLUSIONS:  Task Force members favored the parallel group 
design compared to delayed start or staggered withdrawal clinical trial designs to support disease 
modification.  Amyloid biomarkers were regarded as providing mild support for disease 
modification while tau biomarkers were regarded as providing moderate support.  Combinations of 
biomarkers, particularly combinations of tau and neurodegeneration, were regarded as providing 
moderate to marked support for disease modification and combinations of all three classes of 
biomarkers were regarded by a majority as providing marked support for disease modification.  
Task Force members considered that evidence derived from clinical trials and biomarkers supports 
clinical meaningfulness of an intervention, and when combined with a single clinical trial outcome, 
nearly all regarded the clinical trial design or biomarker evidence as supportive of disease 
modification.  A minority considered biomarker evidence by itself as indicative of disease 
modification in prevention trials.  Levels of evidence (A,B,C) were constructed based on these 
observations. 
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CONCLUSION:  The survey indicates the view of knowledgeable stakeholders regarding evidence 
derived from clinical trial design and biomarkers in support of disease modification.  Results of this 
survey can assist in designing clinical trials of DMTs.   
 
Key words:  Alzheimer’s disease, clinical trials, biomarkers, EU/US Task Force   
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Biomarker and Clinical Trial Design Support for Disease-Modifying 
Therapies:  Report of a Survey of the EU/US  
Alzheimer’s Disease Task Force 
  
 Disease-modifying therapies (DMTs) for Alzheimer’s disease (AD) are an increasingly 
important goal for drug development programs in an effort to prevent or delay the onset or slow 
the progression on the disease [1].  Analyses suggest that a delay of 5 years in the onset of AD by 
2025 would decrease the frequency of the illness by 40% in 2035 and would save an estimated 
$367 billion by 2050[2].  A DMT can be defined as an intervention that produces an enduring 
change in the clinical progression of AD by interfering in the underlying pathophysiological 
mechanisms of the disease process leading to cell death [3, 4].  Sources of data in support of disease 
modification (DM) include observations derived from trial designs and data from biomarkers 
collected in the course of clinical trials [3, 4].   
 To better understand how critical stakeholders view the strength of evidence used to 
support the concept of DM and to construct levels of evidence of DM, we conducted a survey of 
members of the European Union/United States (EU/US) Alzheimer’s Disease Task Force including 
individuals with biopharma industry, academic, and regulatory backgrounds relevant to AD drug 
development.  The Task Force has a history of convening, discussing, and recommending action for 
issues related to clinical trials in AD [5-9].   Based on the results of the survey we suggest levels of 
evidence for DMT clinical trials as ranked by Task Force members.  The purpose of the survey and 
data organization/presentation is to assist those involved in DMT drug development to choose trial 
designs and biomarkers for trials that will best demonstrate DM. 
 
Research Methods 
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The survey was conducted between June 26 and July 11, 2017 and consisted of 4 rounds of 
requests to all members of the EU/US Task Force to complete the survey.  The purpose of the 
survey and the proposed use of the data collected were explained in the request soliciting the 
response.  Ninety-three unique individuals responded to the survey of 107 active members of the 
Task Force for a response rate of 87 %.   
Most of the questions (29/35) querying trial design and biomarker support for DMTs were 
framed as offering “no”, “mild”, “moderate”, or “marked” support for DM.  Two participation 
questions, 3 demographic questions, and 3 yes/no questions were also posed.  The survey reporting 
adheres to established guidelines[10].  Statistical comparisons used the_Bonferroni correction for 
multiple comparisons (6 possible combinations) within the question with an adjusted p-value of 
0.05/6=0.0083 (PercD). 
The survey was reviewed and a waiver for informed consent obtained from the Cleveland 
Clinic Institutional Review Board.  All survey respondents agreed to take the survey and to have 
their responses used in a publication.  All responses were anonymous.  Not all respondents 
answered all questions; no questions had fewer than 70 respondents and most had 80 or more. 
 
Results 
 The survey included demographic information regarding the participants.  Of respondents, 
48.91% were members of the biopharma industry, 38.04% were primarily academicians with 
expertise in AD and DMT, and 13.04% were from other sectors including regulatory authorities.  Of 
the participating Task Force members, 30.34%% were active primarily in the EU, 55.43%% in 
North America, and 14.13% in other world regions.   
Data were collected on the experience of those responding to the survey; 6.59% were 
relatively new to drug development with 0-5 years of experience, 10.99% had 6-10years, 16.48% 
had  11-15 years, 21.98% in 16-20 years, and 43.96% had more than 20years of drug development 
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experience.  Cumulatively the respondents had a minimum of 1478.1 years of experience with 
clinical trials and drug development and more than 80% had at least 10 years of drug development 
experience.   
 The survey queried the respondents on the strength of data offered by types of trial design 
for DM (Table 1).  Staggered start and delayed withdrawal designs have been proposed as means of 
supporting DM [11-13].  Of the respondents, 10.71%, 33.33%, 36.90% and 19.05% thought the 
delayed start design with failure to catch up to the group treated first by the group treated after a 
delay offered no, mild, moderate, and marked support, respectively. The percentage difference 
(PercD) between mild and no support was 22.62% with a 95% confidence interval (CI) of 9.28% - 
35.96%, and the PercD between moderate and no support was 26.19% with a 95% CI of 12.53% - 
39.84%. Similarly, 9.88%, 41.98%, 32.10%, and 16.05% of the respondents thought that the failure 
to fall to baseline levels by the withdrawn group in the delayed withdrawal design offered no, mild, 
moderate, and marked support for DM.  A parallel group design with a drug-placebo difference at 
trial conclusion was considered to offer no support for DM by 32.94%; mild support by 17.65%, 
moderate support by 16.47%, and marked support by 32.94%.   
 
Table 1.  Ratings of clinical trial design evidence in support of disease-modification. 
 
The survey queried observations regarding the slope of decline expected with DMTs.  A 
change in slope of decline was considered to offer no, mild, moderate, and marked support for DM 
by 10.47%, 24.42%, 38.37%, and 26.74% of the respondents.  An increasing drug-placebo 
difference over time was thought to offer no, mild, moderate, and marked support for DM by 9.30%, 
19.77%, 34.88%, and 36.05% of respondents.  Delay to milestone observations (e.g, delay to reach 
Clinical Dementia Rating (CDR) scores of 1.0 from a CDR of 0.5 at baseline) were regarded as 
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supporting no, mild, moderate, and marked support of DM by 19.77%, 29.07%, 36.05%, and 
15.12% of survey respondents.   
 The survey interrogated the support offered for DM by commonly used biomarkers 
including amyloid and tau imaging and cerebrospinal fluid (CSF) measures of amyloid beta protein 
1-42 (Aß), total tau, and phospho-tau (p-tau) (Table 2).  Reduction in amyloid burden as shown by 
amyloid imaging was regarded as offering no, mild, moderate, and marked support by 6.25%, 
52.50%, 30.00%, and 11.25% of respondents (mild support VS no support: PercD=46.25%, 95% 
CI=32.86% - 59.64%; mild support VS marked support: PercD=41.25%, 95% CI=26.27% - 56.23%).  
CSF measures of Aß were regarded similarly (20.25%, 49.37%. 24.05%, 6.33%).   
Changes in tau imaging were regarded as indicative of DM by many respondents (7.69%, 
26.92%, 46.15%, 19.23% considered reduction of tau burden on tau imaging as offering no, mild, 
moderate, and marked support for DM).  Drug-placebo differences in total tau and p-tau were 
considered to offer similar levels of support for DM.  Differences in CSF total tau were considered 
by 9.09%, 54.55%, 28.57%, and 7.70% of respondents to offer no, mild, moderate and marked 
support for DM.  For p-tau, 7.69%, 50.00%, 32.05%, and 10.26% considered drug-placebo 
difference to be indicative of no, mild, moderate, and marked support for DM.    
Drug-placebo differences in fluorodeoxyglucose (FDG) positron emission tomography (PET) 
were considered by 16.46%, 41.77%, 31.65%, and 10.13% of respondents to be indicative of DM.   
Individuals thought changes in volumetric magnetic resonance imaging (MRI) supported 
the occurrence of DM more than drug-placebo differences in functional MRI.  Of the respondents, 
7.69%, 35.90%, 38.46%, and 17.95% thought drug-placebo differences in MRI to offer no, mild, 
moderate, and marked support for DM.  Drug-placebo differences in MRI were generally considered 
less indicative of DM (22.08%, 51.95%, 20.78%, and 5.19% considered fMRI differences between 
drug and placebo to indicate no, mild, moderate, and marked support for DM).   
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Table 2.  Ratings of biomarker evidence in support of disease-modification. 
 
 The survey also queried the combinations of biomarkers that might be supportive of DM by 
a potential DMT.  When considering drug-placebo differences on two amyloid biomarkers (e.g, 
amyloid imaging and CSF Aß), 7.59%, 36.71%, 36.71%, and 18.99% ranked the changes as offering 
no, mild, moderate, and marked support for DM).  This compares to drug-placebo differences in two 
tau-related measures (e.g, tau imaging and CSF tau or p-tau) that was seen by 7.79%, 20.78%, 
49.35%, and 22.08% of respondents as supportive of DM. The percentage of moderate support is 
significantly higher than that of no support (PercD=41.56%, 95% CI=27.45% - 55.66%), mild 
support (PercD=28.57%, 95% CI=10.99% - 46.15%), and marked support (PercD=27.27%, 95% 
CI=9.41% - 45.14%). Drug-placebo differences of combinations of amyloid-related plus tau-related 
measures were considered more indicative of DM:  5.33%, 12.00%, 49.33%, and 33.33% regarded 
the combination as indicating no, mild, moderate, and marked support.  The percentage of 
moderate support or marked support is statistically significantly greater than that of no support or 
mild support. Therapies that produce changes in amyloid measures and volumetric MRI were 
considered by 2.56%, 11.54%, 53.85%, and 32.05% as indicative of no, mild, moderate, or marked 
support of DM.  Drug-placebo differences on the combination of volumetric MRI and measures of 
tau was regarded by 2.53%, 6.33%, 48.10%, and 43.04% of respondents as indicative of DM.  Drug-
placebo differences on the combination of all three types of measures (amyloid, tau, MRI) was most 
likely to be seen by the respondents as supportive of DM:  2.53%, 6.33%, 30.38%, and 60.76% 
thought this combination to support DM. The percentage of marked support is significantly greater 
than that of no support (PercD=58.22%, 95% CI=46.27% - 70.18%), mild support (PercD=54.43%, 
95% CI=40.93% - 67.93%), and moderate support (PercD=30.38%, 95% CI=10.42% - 50.34%). 
 The survey also sought to understand respondents’ views of biomarkers using the Amyloid 
(A), Tau (T), and Neurodegeneration (N) classification of biomarkers [14].  Drug-placebo 
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differences in A were regarded as indicative of DM by 7.79%, 55.84%, 29.87%, and 6.49% (no, mild, 
moderate, marked) of respondents.  Drug-placebo differences in T were regarded as indicative of 
DM by 5.19%, 35.06%, 50.65%, and 9.09% of respondents.  Drug-placebo differences in N were 
perceived as indicative of DM by 2.67%, 34.67%, 41.33%, and 21.33% of respondents.   
The survey also approached drug-placebo differences in combinations of biomarkers using 
the A, T, N approach.  Drug-placebo difference in A plus T were regarded as indicative of DM by 
4.00%, 20.00%, 53.33%, and 22.67% of respondents.  Differences in A plus N were perceived as 
supporting DM by 1.35%, 17.57%, 54.05%, and 27.03% of surveyed individuals.  Of respondents, 
1.32%, 15.79%, 42.11%, and 40.79% thought drug-placebo differences on T plus N to indicate DM.  
Drug-placebo differences on the combination of all three biomarker classes --- A, T, N --- were 
considered by 1.32%, 6.58%, 26.32%, and 65.79% to support DM. 
 
Table 3.  Rating of biomarker Evidence of Disease-Modification using the A, T, N approach (A - 
amyloid biomarkers, T – tau biomarkers, N - neurodegeneration biomarkers) 
 
The survey queried respondents on how biomarker and clinical trial design observations 
related to other types of data in establishing clinical meaningfulness (Figure 1).   Respondents were 
asked whether they thought evidence of DM (from trial designs or biomarkers) supported the 
concept of clinical meaningfulness of an intervention. Two-thirds (67.53%) said “yes” (Figure 1a).  
Respondents were asked if evidence of DM (from trial designs or biomarkers) support clinical 
meaningfulness of an intervention if paired with a positive clinical outcome (e.g, AD Assessment 
Scale-cog subscale, CDR- sum of boxes, Preclinical Alzheimer Cognitive Composite, etc) in a trial of a 
DMT.  Ninety percent (90.67%) responded “yes” to this probe (Figure 1b).  Considering the role of 
biomarkers in prevention trials, respondents were asked if biomarker evidence of successful 
intervention in the fundamental process of cell death could serve as a single primary outcome in 
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prevention trials of participants with normal cognition and biomarker evidence of AD pathology.  
Approximately 40 percent (42.11%) said “yes” (Figure 1c). 
 
Figure 1a,b,c. Percent of respondents with “yes” and “no” answers to each of the probe question. 
 
Discussion 
 Observations from this survey reflect the opinions of a majority of members of the EU/US 
Alzheimer’s Disease Task Force.  Together the respondents represent in excess of 1000 cumulative 
years of drug development experience.  The survey specifically focused on the roles of clinical trial 
design and of biomarkers in supporting DM in clinical trials of AD DMTs.  The survey also queried 
the roles of trial designs and biomarkers in regulatory discussions of clinical meaningfulness.   
 Delayed start and staggered withdrawal designs are frequently discussed as means of 
showing DM in clinical trials[3, 11-13]. There was some ambiguity in the responses obtained for 
trial design.  Although, a minority of EU/EU Task Force members considered these designs as 
offering marked support for DM (19.05% and 16.05% respectively) and parallel group designs 
showing a drug-placebo difference at trial termination were seen as offering marked support for 
DM 32.94%, the three trial designs had very similar percentages when moderate and marked 
support were combined (55.95% for delayed start; 48.15% for staggered withdrawal; 49.41% for 
parallel group). A drug-placebo difference at trial termination in a parallel group trial was regarded 
as showing marked support or no support for DM by exactly equal numbers of Task Force members 
(32.94% and 32.94%).    
A number of secondary observations have been suggested as supportive of DM[3, 4].  When 
considering moderate and marked support together, a majority of Task Force members thought 
that a change in slope of decline and an increasing drug-placebo difference over time offered 
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substantial support for DM (65.11% and 70.93%).  Delay-to-milestone observations were thought 
to provide mostly mild (29.07%) and moderate (36.05%) support for DM. 
 Reductions in amyloid on amyloid imaging and drug-placebo differences in CSF Aß were 
considered to provide marked support for DM by a minority of Task Force members (11.25% for 
amyloid imaging, 6.33% for CSF Aß, and 6.49% for A in the A, T, N classification).  These measures 
were thought to offer moderate support by 30.00%, 24.05%, and 29.87%.   
 Tau imaging was perceived as providing stronger evidence of DM than amyloid imaging.  Of 
the respondents, 19.23% thought tau imaging offered marked support for DM and 46.15% thought 
it offered moderate support (65.38% together).  CSF measures of tau were regarded less 
confidently as supporting DM; total tau was seen as offering marked and moderate support by 
7.79% and 28.57%, while p-tau was perceived as offering marked and moderate support by 
10.26% and 32.05%.  Drug-placebo differences in T of the A, T, N classification were considered to 
offer marked and moderate support for DM by 9.09% and 50.65% (59.74% together).   
Drug-placebo difference on volumetric MRI was considered more supportive of DM than 
either amyloid or tau measures; 17.95% thought if offered marked support for DM and 38.46% 
thought is moderately supportive (56.41% together).  Drug-placebo differences on N of the A, T, N 
classification were perceived as offering marked and moderate support by 21.33% and 41.33% 
(62.66% together).  Drug-placebo difference on FDG PET and fMRI were most commonly 
considered mildly supportive of DM (41.77%, 51.95%).   
 Drug-placebo differences on a combination of two types of amyloid biomarkers were 
considered somewhat supportive of DM (18.99% marked support, 36.71% moderate support).  
Drug-placebo difference on two types of tau biomarkers changed little from the confidence in DM 
derived from tau imaging by itself (22.08% marked and 49.35% moderate support for the 
combination; 19.23% marked and 46.15% moderate for tau imaging by itself).  Drug-placebo 
differences in combinations of biomarkers assessing different pathologies were perceived as 
 13 
supporting DM more strongly than individual or combinations of biomarkers measuring a single 
category of pathological change.  Amyloid plus tau provided marked support for 33.33% of Task 
Force members and 49.33% thought it provided moderate support (81.69% together); for amyloid 
plus MRI changes 32.05% and 53.85% thought the combination provided marked and moderate 
support (85.90% together); for tau plus MRI 44.04% and 48.10% thought the combination 
provided marked and moderate support (91.14% together).  Drug-placebo difference on the 
combination of all three types of biomarkers was thought to be most supportive of DM (60.67% 
marked support).  Overall, the trend was to regard the combination of biomarkers to be more 
indicative of DM than any single biomarker and confidence in DM increased with the number of 
biomarkers demonstrating a drug-placebo difference. 
The A, T, N approach yielded results similar to the biomarker-specific approach (for marked 
support: A+T = 22.67%; A + N = 27.03%; T + N = 40.79% and A+T+N = 65.79%).  The concordance 
between the biomarker-specific rankings and the A, T, N rankings supports the internal validity of 
the survey. 
 Most Task Force members considered trial and biomarker evidence of DM to be clinically 
meaningful (67.53%).  A substantial majority (90.67%) thought that the combination of a clinical 
measure (ADAS-cog, CDR-sb, PACC) plus trial design as biomarker evidence of DM would support 
the clinical meaningfulness of an intervention.  A minority of Task Force members (42.11%) 
thought that biomarker evidence of DM would serve as a single primary outcome in prevention 
trials.   
 Limitations of the survey include the relatively small size of the Task Force; the fact that not 
all respondents answered all questions; the possible ambiguity or misinterpretation of some 
questions; and possible subjective variability in defining “mild”, “moderate”, and “marked”. 
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 Strengths include the experience of the stake holders; the high rate of response among Task 
Force members; and the internal consistency shown across the two biomarker classification 
systems used. 
 One of the goals of the survey was to allow construction of levels of evidence in support of 
DM to assist in guiding planning of trials of DMTs.  Table 4 shows how the survey would guide the 
assignment of levels of evidence supportive of DM.   Based on the percent of Task Force members 
indicating that a trial design or biomarker had marked, moderate or mild support for DM, the 
survey indicates that the trial design most commonly chosen to support DM was the parallel group 
approach (Class A); delayed start and delay-to-milestone designs offered moderate support (Class 
B); and staggered withdrawal designs offered mild support (Class C).  Class A biomarker support 
for DM was based on the combination of A+T+N; Class B evidence included T+N, A+N, A+T, two T, 
two A, volumetric MRI, and tau imaging; Class C evidence included FDG, fMRI, CSF tau, CSF p-tau, 
CSF Aß, and amyloid imaging. 
 
Table 4. Levels of evidence in support of DM as derived from the survey of the EU/US 
Alzheimer’s Disease Task Force.  In each case, the hierarchy is derived from the survey by 
which observation had marked support (Level A), moderate support (Level B), or mild support 
(Level C). 
 
Summary 
 This survey of EU/US Alzheimer’s Disease Task Force members provides insight into the 
opinions of those experienced with development of DMTs for AD.  Cumulatively the respondents 
had nearly 1500 years of drug development experience.  Some clear trends were evident in the 
survey such as the perception that drug-placebo differences in several types of biomarkers offers 
more support for DM than combinations of any two or any single biomarker.  The survey allowed  
 15 
the construction of classes of evidence in support of DM (Table 4).  The survey was designed to 
assist those involved in development of DMTs for AD to choose designs and biomarkers perceived 
by the stakeholders as indicative of DM.  These observations may assist in constructing trials and 
marshalling evidence of DM in trials of urgently needed DMT for AD. 
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Table 1.  Ratings of clinical trial design evidence in support of disease-modification. 
 
 No Support Mild Support Moderate 
Support 
Marked 
Support 
Delayed start design with failure 
to catch up in delayed start 
design 
10.71 33.33 36.90 19.05 
Staggered withdrawal design 
with failure to fall back to 
baseline levels in staggered 
withdrawal design 
9.88 41.98 32.10 16.05 
Parallel group design with drug-
placebo difference at end of trial 
32.84 17.65 16.47 32.94 
Change in slope of decline in 
active treatment group 
compared to placebo 
10.47 24.42 38.37 26.74 
Increasing drug-placebo 
divergence over time 
9.30 19.77 34.88 36.05 
Delay to milestones in the 
course of the trial (e.g, 
progression from CDR 0.5 to 1.) 
19.77 29.07 36.05 15.12 
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Table 2.  Ratings of biomarker evidence in support of disease-modification. 
 
 No 
Support 
Mild 
Support 
Moderate 
Support 
Marked 
Support 
Significant drug-placebo difference on 
reduction of amyloid plaque burden on 
amyloid imaging 
6.25 52.50 30.00 11.25 
Significant drug-placebo difference in 
reduction of CSF Aß1-42 
20.25 49.37 24.05 6.33 
Significant drug-placebo difference on 
reduction of tangle burden on tau imaging 
7.69 26.92 46.15 19.23 
Significant drug-placebo difference in change 
in CSF total tau 
9.09 54.55 28.57 7.79 
Significant drug-placebo difference in change 
in CSF phospho-tau 
7.69 50.00 32.05 10.26 
Significant drug-placebo difference in change 
in FDG PET 
16.46 41.77 31.65 10.13 
Significant drug-placebo difference in change 
in volumetric MRI 
7.69 35.90 38.46 17.95 
Significant drug-placebo difference in change 
in functional MRI 
22.08 51.95 20.78 5.19 
Significant drug-placebo difference in two 
amyloid markers such as amyloid imaging 
and CSF Aß1-42 
7.59 36.71 36.71 18.99 
Significant drug-placebo difference in two 
tau-related markers such as tau imaging and 
CSF tau or p-tau 
7.79 20.78 49.35 22.08 
Significant drug-placebo difference in two 
markers suggesting impact on amyloid AND 
tau pathologies such as amyloid imaging or 
CSF Aß1-42PLUS tau imaging for CSF tau/p-tau 
5.33 12.00 49.33 33.33 
Significant drug-placebo difference in two 
markers suggesting impact on at amyloid 
AND neurodegeneration such as amyloid 
imaging or CSF Aß1-42  PLUS MRI 
2.56 11.54 53.85 32.05 
Significant drug-placebo difference in two 
markers suggesting impact on tau pathology 
AND neurodegeneration such as tau imaging 
or CSF tau/p-tau PLUS MRI 
2.53 6.33 48.10 43.04 
Significant drug-placebo difference in three 
markers suggesting impact on tau AND 
amyloid pathology AND neurodegeneration 
such as amyloid imaging or CSF Aß1-42  PLUS 
tau imaging or CSF tau/p-tau PLUS MRI 
2.53 6.33 30.38 60.76 
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Table 3.  Rating of biomarker Evidence of Disease-Modification using the A, T, N approach 
(A - amyloid biomarkers , T – tau biomarkers, N -  neurodegeneration biomarkers ) 
 No Support Mild Support Moderate 
Support 
Marked 
Support 
Significant drug-placebo 
difference on A 
7.79 55.84 29.87 6.49 
Significant drug-placebo 
difference on T 
5.19 35.06 50.65 9.09 
Significant drug-placebo 
difference on N 
2.67 34.67 41.33 21.33 
Significant drug-placebo 
difference on A PLUS T 
4.00 20.00 53.33 22.67 
Significant drug-placebo 
difference on A PLUS N 
1.35 17.57 54.05 27.03 
Significant drug-placebo 
difference on T PLUS N 
1.32 15.79 42.11 40.79 
Significant drug-placebo 
difference on A PLUS T PLUS N 
1.32 6.85 26.32 65.79 
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Table 4. Levels of evidence in support of DM as derived from the survey of the EU/US 
Alzheimer’s Disease Task Force.  In each case, the hierarchy is derived from the survey by 
which observation had marked support (Level A), moderate support (Level B), or mild 
support (Level C). 
Level of Evidence Type of Evidence Specific Recommendation 
A Clinical trial type Parallel group design* 
 Biomarker type Drug-placebo differences in A+T+N 
B Clinical trial type Delayed start or delay-to-milestone 
 Biomarker type** T+N; A+N; A+T; two T; volumetric MRI; tau 
imaging 
C Clinical trial type Staggered withdrawal, 
 Biomarker type FDG, fMRI, CSF tau, CSF p-tau, CSF Aß, 
amyloid imaging 
 
*Ambiguities concerning this recommendation are provided in the discussion. 
**2 A biomarkers were equally ranked for moderate and mild support of DM. 
 
A = amyloid, T= tau, N = neurodegeneration 
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Figure Legends 
 
Figure 1a,b,c. Percent of respondents with “yes” and “no” answers to each of the probe 
questions. 
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Figure 1a. Percent of respondents with “yes” and “no” answers to the probe question. 
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Figure 1b. Percent of the respondents with “yes” and “no” answers to the probe question. 
 
 
 
 
 
 
 
 
 
 
 
 26 
Figure 1c. Percent of the respondents with “yes” and “no” answers to the probe question. 
 
